FindTrial
Sign In

Optune

DEVICE8 trials

Sponsors

University of Florida, Aarhus University Hospital, Celgene, Baylor Research Institute, Leaf Vertical Inc.

Conditions

GBMGlioblastomaGlioblastoma MultiformeMalignant GliomaMelanoma With Brain MetastasisNewly Diagnosed GlioblastomaRecurrent Glioblastoma

Phase 1

Enhancing Optune Therapy With Targeted Craniectomy
CompletedNCT02893137
Aarhus University HospitalGlioblastoma
Start: 2016-10-01End: 2019-05-31Updated: 2019-11-27
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
CompletedNCT02903069
CelgeneGlioblastoma, Malignant Glioma
Start: 2016-08-17End: 2021-01-25Updated: 2021-04-19
A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma
NCT03687034
Leaf Vertical Inc.Glioblastoma
Start: 2019-06-01End: 2020-12-31Target: 21Updated: 2019-02-26
Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma
CompletedNCT04474353
Stanford UniversityGlioblastoma, Newly Diagnosed Glioblastoma
Start: 2021-05-21End: 2025-09-02Updated: 2025-12-26

Phase 2

TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
TerminatedNCT02663271
University of FloridaGBM, Glioblastoma, Glioblastoma Multiforme +1
Start: 2016-12-19End: 2021-06-11Updated: 2022-06-23
Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis
TerminatedNCT03903640
Washington University School of MedicineMelanoma With Brain Metastasis
Start: 2019-10-14End: 2021-11-03Updated: 2022-06-07
Niraparib/TTFields in GBM
Active, not recruitingNCT04221503
Abramson Cancer Center at Penn MedicineGBM, Glioblastoma, Recurrent Glioblastoma
Start: 2019-12-30End: 2026-01-31Target: 30Updated: 2026-01-08

Unknown Phase

Prognosis and Therapeutic Biomarkers for Glioblastoma Patients
TerminatedNCT03403803
Baylor Research InstituteGlioblastoma
Start: 2017-09-01End: 2019-03-25Updated: 2019-03-27

Related Papers

Validating skullremodeling surgery configuration to enhance TTFields for first recurrence glioblastoma with computational modeling
WFNOS 2022 Abstract Book2022-01-01
Abstract CT103: Final results for OptimalTTF-1: Optimizing Tumor Treating Fields with targeted skull remodeling surgery for first recurrence glioblastoma: Phase 1 trial
Cancer Research2020-08-15
Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors
Neuro-Oncology Advances2020-01-0117 citations
SURG-01. OPTIMALTTF-1: FINAL RESULTS OF A PHASE 1 STUDY: FIRST GLIOBLASTOMA RECURRENCE EXAMINING TARGETED SKULL REMODELING SURGERY TO ENHANCE TUMOR TREATING FIELDS STRENGTH
Neuro-Oncology2019-11-01
P05.03 OptimalTTF-1: Final results of a phase 1 study at first glioblastoma recurrence examining targeted craniotomy to enhance Tumor Treating Fields intensity
Neuro-Oncology2019-08-01
Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).
Journal of Clinical Oncology2019-05-2010 citations
ACTR-43. OPEN-LABEL PHASE 1 CLINICAL TRIAL TESTING PERSONALIZED AND TARGETED SKULL REMODELING SURGERY TO MAXIMIZE TTFIELDS INTENSITY FOR RECURRENT GLIOBLASTOMA – INTERIM ANALYSIS AND SAFETY ASSESSMENT (OPTIMALTTF-1)
Neuro-Oncology2018-11-013 citations
ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS
Neuro-Oncology2018-11-011 citations
ATIM-03. TTFIELDS AND PULSED BEVACIZUMAB IN PATIENTS WITH BEVACIZUMAB-REFRACTORY RECURRENT GLIOBLASTOMA: A PHASE 2 STUDY
Neuro-Oncology2018-11-01
P01.029 Open-label phase 1 clinical trial testing personalized and targeted skull remodeling surgery to maximize TTFields intensity for recurrent glioblastoma - Interim analysis and safety assessment (OptimalTTF-1)
Neuro-Oncology2018-09-01
ATRT-18. VALIDATION OF PROTEASOME INHIBITION AS A THERAPEUTIC TARGET IN ATYPICAL TERATOID/RHABDOID TUMORS
Neuro-Oncology2018-06-01
A phase 1, multicenter, open-label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed WHO grade IV malignant glioma (glioblastoma, ndGBM): Dose-escalation results.
Journal of Clinical Oncology2018-05-206 citations
ACTR-29. A PHASE 2 STUDY OF TTFIELDS AND PULSED BEVACIZUMAB IN PATIENTS WITH BEVACIZUMAB-REFRACTORY RECURRENT GLIOBLASTOMA
Neuro-Oncology2017-11-01
ACTR-45. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM)
Neuro-Oncology2017-11-01
ACTR-54. OPEN-LABEL PHASE 1 CLINICAL TRIAL TESTING PERSONALIZED AND TARGETED INTERVENTION WITH SKULL REMODELLING SURGERY TO MAXIMIZE LEVELS OF TTFIELDS INTENSITY FOR HIGHER TREATMENT BENEFIT - THE OPTIMAL TTF STUDY
Neuro-Oncology2017-11-01